Larry A Harshyne Jr

Larry A. Harshyne, PhD

Contact Dr. Harshyne

1020 Locust Street
Jefferson Alumni Hall
Suite 454
Philadelphia, PA 19107

(215) 503-9893

Most Recent Peer-reviewed Publications

  1. Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer
  2. Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes
  3. Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes
  4. Human parechovirus and enterovirus initiate distinct CNS innate immune responses: Pathogenic and diagnostic implications
  5. Immune biomarkers of treatment failure for a patient on a phase i clinical trial of pembrolizumab plus radiotherapy
  6. Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients
  7. Enhancement of glioma-specific immunity in mice by “NOBEL”, an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide
  8. Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm
  9. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers
  10. c-Jun NH2-terminal kinase 2α2 promotes the tumorigenicity of human glioblastoma cells
  11. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells
  12. A role for class A scavenger receptor in dendritic cell nibbling from live cells
  13. Novel Training Concepts and Techniques Used to Increase Safety Awareness in the Laboratory Animal Facility
  14. Changes in dendritic cell migration and activation during SIV infection suggest a role in initial viral spread and eventual immunosuppression
  15. Erratum: Dendritic cells acquire antigens from live cells for cross-presentation to CTL. (The Journal of Immunology (2001) 166 (3717-3723))
  16. Dendritic cells acquire antigens from live cells for cross-presentation to CTL
  17. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: Implications for dendritic cell-based vaccines